CME: Mesothelioma management: therapeutic updates and best practices
Cost: FreeView Offer chevron_right
Mesothelioma is a malignancy that occurs in mesothelium, an epithelial layer that lines the pleurae, peritoneum, pericardium, the testes’ tunica vaginalis and tunica serosa uteri. Malignant mesothelioma (MM) may occur in any area that is composed of mesothelial cells, but the most common site is in the pleural space (81%) in cases of malignant pleural mesothelioma (MPM), followed by peritoneum (9%).. In United States, approximately 3,200 new cases of MM are diagnosed each year, and it mostly affects older white male with median age of 62 at diagnosis for MPM and a slightly younger median age for peritoneal MM. Whites are twice as likely to develop MM as blacks, and males are four times as likely as females. The largest risk factor for MM is a history of asbestos exposure: over 80% of MPM patients and 33% of patients with peritoneal MM have a documented prior exposure.
By the end of the session the participant will be able to:
- Review the incidence, diagnosis, and histology of mesothelioma
- Describe the pathology of pleural mesothelioma and the roles of angiogenesis and associated growth factor signaling pathways
- Describe existing unmet needs in improving outcomes for patients with mesothelioma, including prolonging progression-free and overall survival
- Describe present standards of care in the treatment of patients with mesothelioma and apply them to patient cases
- Describe emerging therapies for mesothelioma and the data behind them, including anti-angiogenic agents, such as oral angiokinase inhibitors, and tumor treating fields
Healthcare professionals including: medical oncologists, primary care physicians, and pathologists; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with mesothelioma.